Ginkgo Bioworks Organism designers at Ginkgo evaluate genetic designs that will then be built and tested in the adjacent organism foundry, Bioworks1.
Home » Emerging technologies » Organism engineering » Ginkgo Bioworks and Amyris Join Forces to Facilitate Bioproducts Commercialization

Ginkgo Bioworks and Amyris Join Forces to Facilitate Bioproducts Commercialization

Ginkgo Bioworks, the organism company, announced today that it will collaborate with the industrial bioproducts company, Amyris. The coalition will enable both companies to develop products more efficiently, at a larger scale, and reaching market quicker.

“Ginkgo and Amyris working together sets the gold standard for the industrial biotechnology industry,” said the CEO of Ginkgo Bioworks, Jason Kelly. “Each company was seeing more customer demand for partnerships than we could handle individually. By sharing our assets and experience we can offer more customers access to the industry-leading technology platform.”

As part of the new arrangement, Ginkgo Bioworks will help Amyris’ strain engineering capability via use of its world-class foundry. Utilizing this platform, Amyris will then be bring products to scale. The two companies collectively have over 70 products under contract to be delivered to the world’s leading brands in industrial, health and personal care markets.  

In the industry of scaling highly engineered organisms and delivering breakthrough products, Amyris has an excellent track record. For making cultured ingredients such as flavors, fragrances, nutritional ingredients and sweeteners, Amyris uses its well-suited fermentation facility in Brazil. In the next three years, the partnership is planning to deliver over 20 new products.

Bioworks2, Ginkgo’s new next-generation automated foundry, is currently under construction. Here, Ginkgo’s organism engineers will be able to develop new designs at large scale. The automated facility is 25,000 square-feet and will be utilized for building and testing prototypes of engineered microbes. It is their second such facility, and it is a huge technological step up from Bioworks1, which opened in early 2015.   

“Our combined companies have the leading product and customer portfolio and we realized a need to find a faster and more predictable approach to deliver products to these customers and markets,” said John Melo, CEO of Amyris. “Amyris has successfully commercialized five products from highly engineered molecules, disrupting markets from skin care, fragrances, to industrial lubricants, tires and jet fuel. The flood of new products in the coming years will prove that industrial biotechnology’s time has arrived.”

0

Julia Turan

Julia Turan triturated, pipetted, imaged, and analyzed, during her undergrad years studying neurobiology. Since then, she has shifted into the world of science communications, hoping to promote a language of science legible to all. Julia is currently completing an MSc in Science Communication and Public Engagement at the University of Edinburgh.

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Add comment

Job opportunities

More